129 related articles for article (PubMed ID: 35323988)
1.
Forgione MO; McClure BJ; Page EC; Yeung DT; Eadie LN; White DL
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35323988
[TBL] [Abstract][Full Text] [Related]
2. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
3. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling.
Kirsanov K; Fetisov T; Lesovaya EA; Maksimova V; Trukhanova L; Antoshina E; Gor'kova T; Morozova O; Safina A; Fleyshman D; Salimov R; Shipaeva E; Ivanov R; Leonov A; Purmal AA; Belitsky GA; Gudkov AV; Gurova KV; Yakubovskaya MG
Cancer Prev Res (Phila); 2020 Jan; 13(1):53-64. PubMed ID: 31653646
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers.
Dallavalle S; Mattio LM; Artali R; Musso L; Aviñó A; Fàbrega C; Eritja R; Gargallo R; Mazzini S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204214
[TBL] [Abstract][Full Text] [Related]
7. CBL0137 administration suppresses human hepatocellular carcinoma cells proliferation and induces apoptosis associated with multiple cell death related proteins.
Albahde MAH; Zhang P; Chen H; Wang W
Neoplasma; 2020 May; 67(3):547-556. PubMed ID: 32202904
[TBL] [Abstract][Full Text] [Related]
8. Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms.
Jin MZ; Xia BR; Xu Y; Jin WL
Front Oncol; 2018; 8():598. PubMed ID: 30581774
[TBL] [Abstract][Full Text] [Related]
9. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
Front Oncol; 2022; 12():863329. PubMed ID: 35677155
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy.
Chen M; Brackett CM; Burdelya LG; Punnanitinont A; Patnaik SK; Matsuzaki J; Odunsi AO; Gudkov AV; Singh AK; Repasky EA; Gurova KV
Cancer Immunol Immunother; 2021 Jul; 70(7):2073-2086. PubMed ID: 33439292
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M
Clin Cancer Res; 2021 Aug; 27(15):4338-4352. PubMed ID: 33994371
[TBL] [Abstract][Full Text] [Related]
12. Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo.
Fetisov TI; Borunova AA; Antipova AS; Antoshina EE; Trukhanova LS; Gorkova TG; Zuevskaya SN; Maslov A; Gurova K; Gudkov A; Lesovaya EA; Belitsky GA; Yakubovskaya MG; Kirsanov KI
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672738
[TBL] [Abstract][Full Text] [Related]
13. Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.
Singh A; Pruett N; Dixit S; Gara SK; Wang H; Pahwa R; Schrump DS; Hoang CD
J Exp Clin Cancer Res; 2023 Nov; 42(1):304. PubMed ID: 37974213
[TBL] [Abstract][Full Text] [Related]
14. Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a.
Sergeev A; Vorobyov A; Yakubovskaya M; Kirsanova O; Gromova E
Bioorg Med Chem Lett; 2020 Aug; 30(16):127296. PubMed ID: 32631516
[TBL] [Abstract][Full Text] [Related]
15. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
Cucchi DGJ; Bachas C; Klein K; Huttenhuis S; Zwaan CM; Ossenkoppele GJ; Janssen JMWM; Kaspers GL; Cloos J
Br J Haematol; 2020 Mar; 188(5):736-739. PubMed ID: 31588562
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.
Aldoss I; Zhang J; Pillai R; Shouse G; Sanchez JF; Mei M; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Br J Haematol; 2019 Oct; 187(2):e45-e48. PubMed ID: 31441045
[No Abstract] [Full Text] [Related]
18. Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.
van der Helm LH; Berger G; Diepstra A; Huls G; Vellenga E
Br J Haematol; 2017 Sep; 178(5):810-812. PubMed ID: 27431572
[No Abstract] [Full Text] [Related]
19. Curaxin CBL0137 has the potential to reverse HIV-1 latency.
Jean MJ; Zhou D; Fiches G; Kong W; Huang H; Purmal A; Gurova K; Santoso NG; Zhu J
J Med Virol; 2019 Aug; 91(8):1571-1576. PubMed ID: 30989696
[TBL] [Abstract][Full Text] [Related]
20. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
Fitzpatrick MJ; Boiocchi L; Fathi AT; Brunner AM; Hasserjian RP; Nardi V
Histopathology; 2022 Oct; 81(4):496-510. PubMed ID: 35869818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
